Vinpocetine in Patients With Parkinsonian Disease

NCT07229664 — Phase 2 / Phase 3, Recruiting, 60 participants, Tanta University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease

Registry	NCT07229664
Status	Recruiting
Phase	Phase 2 / Phase 3
Study type	Interventional; randomized, parallel, masking: double, treatment
Enrollment	60 (Estimated)
Sponsor	Tanta University (Other)
Conditions	Parkinson Disease
Interventions	Levodopa Carbidopa, Vinpocetine (Drug)
Dates	start 2025-11-10, primary completion 2026-11-20 (estimated), completion 2027-11-20 (estimated), first posted 2025-11-17, last updated 2025-12-10
Locations	1 site in Egypt

-Summary

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Control group	Active comparator	Drug: Levodopa Carbidopa	Control group (Levo-dopa group, n =30) who will receive levodopa/carbidopa (125/12.5 mg) three times daily for 6 months
Vinpocetine group	Active comparator	Drug: Levodopa Carbidopa; Drug: Vinpocetine	Patients will receive levodopa/carbidopa (125/12.5 mg) three times daily plus vinpocetine 10 mg three times daily for 6 months

Levodopa Carbidopa (Drug): Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease.
Vinpocetine (Drug): VIN, a phosphodiesterase-1 (PDE1) inhibitor, reduces oxidative stress and neuroinflammation and is used clinically for cerebrovascular disease and dementia. In PD, VIN increases dopamine levels, protects dopaminergic neurons, reverses motor impairments, and reduces inflammatory mediators

+Outcome measures

Primary outcomes

Change in The Unified Parkinson's Disease Rating Scale (UPDRS). [6 months]: The unified Parkinson's disease rating scale is used to follow the longitudinal course of Parkinson's disease. The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.

Secondary outcomes

changes in serum biomarkers [6 months]: The secondary endpoint is estimated by changes in serum biomarkers such as α-synuclein and Toll like receptor 4

+Eligibility

Sex: All, ages: 50 Years to 70 Years

Inclusion Criteria:

Age ≥ 50 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Exclusion Criteria:

Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications

+Locations (1)

Facility	City	Country	Status
Tanta Unuversity	Tanta	Egypt	Recruiting